Low brain endocannabinoids associated with persistent non-goal directed nighttime hyperactivity after traumatic brain injury in mice.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 09 2020
10 09 2020
Historique:
received:
25
03
2020
accepted:
13
07
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Traumatic brain injury (TBI) is a frequent cause of chronic headache, fatigue, insomnia, hyperactivity, memory deficits, irritability and posttraumatic stress disorder. Recent evidence suggests beneficial effects of pro-cannabinoid treatments. We assessed in mice levels of endocannabinoids in association with the occurrence and persistence of comparable sequelae after controlled cortical impact in mice using a set of long-term behavioral observations in IntelliCages, motor and nociception tests in two sequential cohorts of TBI/sham mice. TBI mice maintained lower body weights, and they had persistent low levels of brain ethanolamide endocannabinoids (eCBs: AEA, OEA, PEA) in perilesional and subcortical ipsilateral brain tissue (6 months), but rapidly recovered motor functions (within days), and average nociceptive responses were within normal limits, albeit with high variability, ranging from loss of thermal sensation to hypersensitivity. TBI mice showed persistent non-goal directed nighttime hyperactivity, i.e. they visited rewarding and non-rewarding operant corners with high frequency and random success. On successful visits, they made more licks than sham mice resulting in net over-licking. The lower the eCBs the stronger was the hyperactivity. In reward-based learning and reversal learning tasks, TBI mice were not inferior to sham mice, but avoidance memory was less stable. Hence, the major late behavioral TBI phenotype was non-goal directed nighttime hyperactivity and "over-licking" in association with low ipsilateral brain eCBs. The behavioral phenotype would agree with a "post-TBI hyperactivity disorder". The association with persistently low eCBs in perilesional and subcortical regions suggests that eCB deficiency contribute to the post-TBI psychopathology.
Identifiants
pubmed: 32913220
doi: 10.1038/s41598-020-71879-x
pii: 10.1038/s41598-020-71879-x
pmc: PMC7483739
doi:
Substances chimiques
Endocannabinoids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14929Références
Corps, K. N., Roth, T. L. & McGavern, D. B. Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol. 72, 355–362. https://doi.org/10.1001/jamaneurol.2014.3558 (2015).
doi: 10.1001/jamaneurol.2014.3558
pubmed: 25599342
pmcid: 5001842
Chauhan, N. B. Chronic neurodegenerative consequences of traumatic brain injury. Restor. Neurol. Neurosci. 32, 337–365. https://doi.org/10.3233/rnn-130354 (2014).
doi: 10.3233/rnn-130354
pubmed: 24398724
Gardner, R. C., Langa, K. M. & Yaffe, K. Subjective and objective cognitive function among older adults with a history of traumatic brain injury: A population-based cohort study. PLoS Med. 14, e1002246. https://doi.org/10.1371/journal.pmed.1002246 (2017).
doi: 10.1371/journal.pmed.1002246
pubmed: 28267747
pmcid: 5340352
Iljazi, A. et al. Post-traumatic stress disorder after traumatic brain injury—a systematic review and meta-analysis. Neurol. Sci. https://doi.org/10.1007/s10072-020-04458-7 (2020).
doi: 10.1007/s10072-020-04458-7
pubmed: 32415640
van der Naalt, J. et al. Early predictors of outcome after mild traumatic brain injury (UPFRONT): An observational cohort study. Lancet Neurol. 16, 532–540. https://doi.org/10.1016/s1474-4422(17)30117-5 (2017).
doi: 10.1016/s1474-4422(17)30117-5
pubmed: 28653646
Leung, A. et al. rTMS in alleviating mild TBI related headaches–a case series. Pain Physician 19, E347-354 (2016).
doi: 10.36076/ppj/2016.19.E347
Khoury, S. & Benavides, R. Pain with traumatic brain injury and psychological disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 87, 224–233. https://doi.org/10.1016/j.pnpbp.2017.06.007 (2018).
doi: 10.1016/j.pnpbp.2017.06.007
pubmed: 28627447
Choi, G. S., Kwak, S. G., Lee, H. D. & Chang, M. C. Effect of high-frequency repetitive transcranial magnetic stimulation on chronic central pain after mild traumatic brain injury: A pilot study. J. Rehabil. Med. 50, 246–252. https://doi.org/10.2340/16501977-2321 (2018).
doi: 10.2340/16501977-2321
pubmed: 29392332
Leung, A. et al. Pain-related white matter tract abnormalities in mild traumatic brain injury patients with persistent headache. Mol. Pain 14, 1744806918810297. https://doi.org/10.1177/1744806918810297 (2018).
doi: 10.1177/1744806918810297
pubmed: 30324850
pmcid: 6311536
Leung, A. et al. Diminished supraspinal pain modulation in patients with mild traumatic brain injury. Mol. Pain https://doi.org/10.1177/1744806916662661 (2016).
doi: 10.1177/1744806916662661
pubmed: 27531671
pmcid: 4989585
Widerstrom-Noga, E., Govind, V., Adcock, J. P., Levin, B. E. & Maudsley, A. A. Subacute pain after traumatic brain injury is associated with lower insular N-acetylaspartate concentrations. J. Neurotrauma 33, 1380–1389. https://doi.org/10.1089/neu.2015.4098 (2016).
doi: 10.1089/neu.2015.4098
pubmed: 26486760
pmcid: 4931745
Jang, S. H., Park, S. M. & Kwon, H. G. Relation between injury of the periaqueductal gray and central pain in patients with mild traumatic brain injury: Observational study. Medicine (Baltimore) 95, e4017. https://doi.org/10.1097/md.0000000000004017 (2016).
doi: 10.1097/md.0000000000004017
Scholz, J. & Woolf, C. J. Can we conquer pain?. Nat. Neurosci. 5(Suppl), 1062–1067. https://doi.org/10.1038/nn942 (2002).
doi: 10.1038/nn942
pubmed: 12403987
Katona, I. & Freund, T. F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 14, 923–930. https://doi.org/10.1038/nm.f.1869 (2008).
doi: 10.1038/nm.f.1869
pubmed: 18776886
Lotsch, J., Weyer-Menkhoff, I. & Tegeder, I. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. Eur. J. Pain https://doi.org/10.1002/ejp.1148 (2017).
doi: 10.1002/ejp.1148
pubmed: 29160600
Davies, A. J. et al. Hedonic drinking engages a supraspinal inhibition of thermal nociception in adult rats. Pain 160, 1059–1069. https://doi.org/10.1097/j.pain.0000000000001482 (2019).
doi: 10.1097/j.pain.0000000000001482
pubmed: 31008815
Pottker, B. et al. Traumatic brain injury causes long-term behavioral changes related to region-specific increases of cerebral blood flow. Brain Struct. Funct. https://doi.org/10.1007/s00429-017-1452-9 (2017).
doi: 10.1007/s00429-017-1452-9
pubmed: 28589257
Kathuria, S. et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76–81 (2003).
doi: 10.1038/nm803
Moise, A. M., Eisenstein, S. A., Astarita, G., Piomelli, D. & Hohmann, A. G. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology 200, 333–346. https://doi.org/10.1007/s00213-008-1209-5 (2008).
doi: 10.1007/s00213-008-1209-5
pubmed: 18545985
pmcid: 2694060
Magid, L. et al. Role of CB2 receptor in the recovery of mice after traumatic brain injury. J. Neurotrauma 36, 1836–1846. https://doi.org/10.1089/neu.2018.6063 (2019).
doi: 10.1089/neu.2018.6063
pubmed: 30489198
pmcid: 6551996
Panikashvili, D. et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413, 527–531. https://doi.org/10.1038/35097089 (2001).
doi: 10.1038/35097089
pubmed: 11586361
Chiarlone, A. et al. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc. Natl. Acad. Sci. USA 111, 8257–8262. https://doi.org/10.1073/pnas.1400988111 (2014) ((Epub 1400982014 May 1400988119)).
doi: 10.1073/pnas.1400988111
pubmed: 24843137
Marsicano, G. et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84–88 (2003).
doi: 10.1126/science.1088208
Braun, M. et al. Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain. Behav. Immun. 68, 224–237. https://doi.org/10.1016/j.bbi.2017.10.021 (2018).
doi: 10.1016/j.bbi.2017.10.021
pubmed: 29079445
Amenta, P. S., Jallo, J. I., Tuma, R. F., Hooper, D. C. & Elliott, M. B. Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. J. Neuroinflammation 11, 191. https://doi.org/10.1186/s12974-014-0191-6 (2014).
doi: 10.1186/s12974-014-0191-6
pubmed: 25416141
pmcid: 4248435
Amenta, P. S., Jallo, J. I., Tuma, R. F. & Elliott, M. B. A cannabinoid type 2 receptor agonist attenuates blood–brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J. Neurosci. Res. 90, 2293–2305. https://doi.org/10.1002/jnr.23114 (2012).
doi: 10.1002/jnr.23114
pubmed: 22903455
Selvaraj, P., Wen, J., Tanaka, M. & Zhang, Y. Therapeutic effect of a novel fatty acid amide hydrolase inhibitor PF04457845 in the repetitive closed head injury mouse model. J. Neurotrauma 36, 1655–1669. https://doi.org/10.1089/neu.2018.6226 (2019).
doi: 10.1089/neu.2018.6226
pubmed: 30526351
Tchantchou, F. et al. The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Neuropharmacology 85, 427–439. https://doi.org/10.1016/j.neuropharm.2014.06.006 (2014).
doi: 10.1016/j.neuropharm.2014.06.006
pubmed: 24937045
pmcid: 4437642
Schurman, L. D. & Lichtman, A. H. Endocannabinoids: A promising impact for traumatic brain injury. Front. Pharmacol. 8, 69. https://doi.org/10.3389/fphar.2017.00069 (2017).
doi: 10.3389/fphar.2017.00069
pubmed: 28261100
pmcid: 5314139
Nguyen, B. M. et al. Effect of marijuana use on outcomes in traumatic brain injury. Am. Surg. 80, 979–983 (2014).
doi: 10.1177/000313481408001015
Firsching, R. et al. Early survival of comatose patients after severe traumatic brain injury with the dual cannabinoid CB1/CB2 receptor agonist KN38-7271: A randomized, double-blind, placebo-controlled phase II trial. J. Neurol. Surg. A Cent. Eur. Neurosurg. 73, 204–216. https://doi.org/10.1055/s-0032-1304815 (2012).
doi: 10.1055/s-0032-1304815
pubmed: 22696266
Rabinak, C. A. et al. Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: A preliminary study. Psychopharmacology 237, 1813–1826. https://doi.org/10.1007/s00213-020-05499-8 (2020).
doi: 10.1007/s00213-020-05499-8
pubmed: 32162103
Sbarski, B. & Akirav, I. Cannabinoids as therapeutics for PTSD. Pharmacol. Ther. https://doi.org/10.1016/j.pharmthera.2020.107551 (2020).
doi: 10.1016/j.pharmthera.2020.107551
pubmed: 32311373
Cohen, J., Wei, Z., Phang, J., Laprairie, R. B. & Zhang, Y. Cannabinoids as an emerging therapy for posttraumatic stress disorder and substance use disorders. J. Clin. Neurophysiol. 37, 28–34. https://doi.org/10.1097/wnp.0000000000000612 (2020).
doi: 10.1097/wnp.0000000000000612
pubmed: 31895187
Burda, J. E., Bernstein, A. M. & Sofroniew, M. V. Astrocyte roles in traumatic brain injury. Exp. Neurol. 275, 305–315. https://doi.org/10.1016/j.expneurol.2015.1003.1020 (2016) ((Epub 2015 Mar 1028)).
doi: 10.1016/j.expneurol.2015.1003.1020
pubmed: 25828533
Pernici, C. D., Kemp, B. S. & Murray, T. A. Time course images of cellular injury and recovery in murine brain with high-resolution GRIN lens system. Sci. Rep. 9, 7946. https://doi.org/10.1038/s41598-019-44174-7 (2019).
doi: 10.1038/s41598-019-44174-7
pubmed: 31138885
pmcid: 6538613
Ratliff, W. A. et al. Effect of mild blast-induced TBI on dendritic architecture of the cortex and hippocampus in the mouse. Sci. Rep. 10, 2206. https://doi.org/10.1038/s41598-020-59252-4 (2020).
doi: 10.1038/s41598-020-59252-4
pubmed: 32042033
pmcid: 7010659
Haller, J., Goldberg, S. R., Pelczer, K. G., Aliczki, M. & Panlilio, L. V. The effects of anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats. Psychopharmacology 230, 353–362. https://doi.org/10.1007/s00213-013-3161-2 (2013).
doi: 10.1007/s00213-013-3161-2
pubmed: 23743650
Griebel, G. et al. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Sci. Rep. 8, 2416. https://doi.org/10.1038/s41598-018-20895-z (2018).
doi: 10.1038/s41598-018-20895-z
pubmed: 29403000
pmcid: 5799259
Cristino, L., Bisogno, T. & Di Marzo, V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 16, 9–29. https://doi.org/10.1038/s41582-019-0284-z (2020).
doi: 10.1038/s41582-019-0284-z
pubmed: 31831863
Mechoulam, R. & Shohami, E. Endocannabinoids and traumatic brain injury. Mol. Neurobiol. 36, 68–74. https://doi.org/10.1007/s12035-007-8008-6 (2007).
doi: 10.1007/s12035-007-8008-6
pubmed: 17952651
Katz, P. S. et al. Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. J. Neurotrauma 32, 297–306. https://doi.org/10.1089/neu.2014.3508 (2015).
doi: 10.1089/neu.2014.3508
pubmed: 25166905
pmcid: 4348366
Gebremedhin, D., Lange, A. R., Campbell, W. B., Hillard, C. J. & Harder, D. R. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca
pubmed: 10362691
Ludanyi, A. et al. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J. Neurosci. 28, 2976–2990 (2008).
doi: 10.1523/JNEUROSCI.4465-07.2008
Monory, K. et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51, 455–466. https://doi.org/10.1016/j.neuron.2006.07.006 (2006).
doi: 10.1016/j.neuron.2006.07.006
pubmed: 16908411
pmcid: 1769341
Esposito, E. & Cuzzocrea, S. Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol. Disord. Drug Targets 12, 55–61 (2013).
doi: 10.2174/1871527311312010010
Ahmad, A. et al. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain. Behav. Immun. 26, 1310–1321. https://doi.org/10.1016/j.bbi.2012.07.021 (2012).
doi: 10.1016/j.bbi.2012.07.021
pubmed: 22884901
Aghaei, I. et al. Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors. Epilepsy Res. 117, 23–28. https://doi.org/10.1016/j.eplepsyres.2015.1008.1010 (2015) ((Epub 2015 Aug 1014)).
doi: 10.1016/j.eplepsyres.2015.1008.1010
pubmed: 26370914
Post, J. M. et al. Antiepileptogenic effect of subchronic palmitoylethanolamide treatment in a mouse model of acute epilepsy. Front. Mol. Neurosci. 11, 67. https://doi.org/10.3389/fnmol.2018.00067.eCollection02018 (2018).
doi: 10.3389/fnmol.2018.00067.eCollection02018
pubmed: 29593494
pmcid: 5861196
Rodriguez de Fonseca, F. et al. An anorexic lipid mediator regulated by feeding. Nature 414, 209–212. https://doi.org/10.1038/35102582 (2001).
doi: 10.1038/35102582
pubmed: 11700558
Suardiaz, M., Estivill-Torrus, G., Goicoechea, C., Bilbao, A. & Rodriguez de Fonseca, F. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 133, 99–110. https://doi.org/10.1016/j.pain.2007.03.008 (2007).
doi: 10.1016/j.pain.2007.03.008
pubmed: 17449181
Soria-Gomez, E. et al. Oleoylethanolamide affects food intake and sleep-waking cycle through a hypothalamic modulation. Pharmacol. Res. 61, 379–384. https://doi.org/10.1016/j.phrs.2010.01.010 (2010).
doi: 10.1016/j.phrs.2010.01.010
pubmed: 20100574
Campolongo, P. et al. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc. Natl. Acad. Sci. USA 106, 8027–8031. https://doi.org/10.1073/pnas.0903038106 (2009).
doi: 10.1073/pnas.0903038106
pubmed: 19416833
Wilker, S. et al. Endocannabinoid concentrations in hair are associated with PTSD symptom severity. Psychoneuroendocrinology 67, 198–206. https://doi.org/10.1016/j.psyneuen.2016.02.010 (2016).
doi: 10.1016/j.psyneuen.2016.02.010
pubmed: 26923850
Neumeister, A. et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Mol. Psychiatry 18, 1034–1040. https://doi.org/10.1038/mp.2013.61 (2013).
doi: 10.1038/mp.2013.61
pubmed: 23670490
pmcid: 3752332
Cantu, D. et al. Traumatic brain injury increases cortical glutamate network activity by compromising GABAergic control. Cereb. Cortex 25, 2306–2320. https://doi.org/10.1093/cercor/bhu041 (2015).
doi: 10.1093/cercor/bhu041
pubmed: 24610117
Drexel, M. et al. Expression of GABA receptor subunits in the hippocampus and thalamus after experimental traumatic brain injury. Neuropharmacology 88, 122–133. https://doi.org/10.1016/j.neuropharm.2014.08.023 (2015).
doi: 10.1016/j.neuropharm.2014.08.023
pubmed: 25229716
pmcid: 4239297
Almeida-Suhett, C. P. et al. Reduced GABAergic inhibition in the basolateral amygdala and the development of anxiety-like behaviors after mild traumatic brain injury. PLoS One 9, e102627. https://doi.org/10.1371/journal.pone.0102627 (2014).
doi: 10.1371/journal.pone.0102627
pubmed: 25047645
pmcid: 4105413
Wenzel, J. M. & Cheer, J. F. Endocannabinoid regulation of reward and reinforcement through interaction with dopamine and endogenous opioid signaling. Neuropsychopharmacology 43, 103–115. https://doi.org/10.1038/npp.2017.126 (2018).
doi: 10.1038/npp.2017.126
pubmed: 28653666
Mahler, S. V., Smith, K. S. & Berridge, K. C. Endocannabinoid hedonic hotspot for sensory pleasure: Anandamide in nucleus accumbens shell enhances “liking” of a sweet reward. Neuropsychopharmacology 32, 2267–2278. https://doi.org/10.1038/sj.npp.1301376 (2007).
doi: 10.1038/sj.npp.1301376
pubmed: 17406653
Hardt, S., Fischer, C., Vogel, A., Wilken-Schmitz, A. & Tegeder, I. Distal infraorbital nerve injury: A model for persistent facial pain in mice. Pain 160, 1431–1447. https://doi.org/10.1097/j.pain.0000000000001518 (2019).
doi: 10.1097/j.pain.0000000000001518
pubmed: 30747909
Matynia, A. et al. Peripheral sensory neurons expressing melanopsin respond to light. Front. Neural Circ. 10, 60. https://doi.org/10.3389/fncir.2016.00060 (2016).
doi: 10.3389/fncir.2016.00060
Bree, D. & Levy, D. Development of CGRP-dependent pain and headache related behaviours in a rat model of concussion: Implications for mechanisms of post-traumatic headache. Cephalalgia https://doi.org/10.1177/0333102416681571 (2016).
doi: 10.1177/0333102416681571
pubmed: 27899434
pmcid: 6454269
Mustafa, G. et al. Trigeminal neuroplasticity underlies allodynia in a preclinical model of mild closed head traumatic brain injury (cTBI). Neuropharmacology 107, 27–39. https://doi.org/10.1016/j.neuropharm.2016.03.016 (2016).
doi: 10.1016/j.neuropharm.2016.03.016
pubmed: 26972829
Tyburski, A. L., Cheng, L., Assari, S., Darvish, K. & Elliott, M. B. Frequent mild head injury promotes trigeminal sensitivity concomitant with microglial proliferation, astrocytosis, and increased neuropeptide levels in the trigeminal pain system. J. Headache Pain 18, 16. https://doi.org/10.1186/s10194-017-0726-1 (2017).
doi: 10.1186/s10194-017-0726-1
pubmed: 28176234
pmcid: 5296267
MacDonald, S. W., Li, S. C. & Bäckman, L. Neural underpinnings of within-person variability in cognitive functioning. Psychol. Aging 24, 792–808. https://doi.org/10.1037/a0017798 (2009).
doi: 10.1037/a0017798
pubmed: 20025396
Vaughn, L. K. et al. Endocannabinoid signalling: Has it got rhythm?. Br. J. Pharmacol. 160, 530–543. https://doi.org/10.1111/j.1476-5381.2010.00790.x (2010).
doi: 10.1111/j.1476-5381.2010.00790.x
pubmed: 20590563
pmcid: 2931554
Valenti, M. et al. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell. Mol. Life Sci. 61, 945–950. https://doi.org/10.1007/s00018-003-3453-5 (2004).
doi: 10.1007/s00018-003-3453-5
pubmed: 15095014
Murillo-Rodriguez, E., Desarnaud, F. & Prospero-Garcia, O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci. 79, 30–37. https://doi.org/10.1016/j.lfs.2005.12.028 (2006).
doi: 10.1016/j.lfs.2005.12.028
pubmed: 16434061
Perez-Morales, M., Fajardo-Valdez, A., Mendez-Diaz, M., Ruiz-Contreras, A. E. & Prospero-Garcia, O. 2-Arachidonoylglycerol into the lateral hypothalamus improves reduced sleep in adult rats subjected to maternal separation. NeuroReport 25, 1437–1441. https://doi.org/10.1097/wnr.0000000000000287 (2014).
doi: 10.1097/wnr.0000000000000287
pubmed: 25356522
Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M. & Mechoulam, R. Endocannabinoids and traumatic brain injury. Br. J. Pharmacol. 163, 1402–1410. https://doi.org/10.1111/j.1476-5381.2011.01343.x (2011).
doi: 10.1111/j.1476-5381.2011.01343.x
pubmed: 21418185
pmcid: 3165950
Honig, M. G. et al. Amelioration of visual deficits and visual system pathology after mild TBI via the cannabinoid Type-2 receptor inverse agonism of raloxifene. Exp. Neurol. 322, 113063. https://doi.org/10.1016/j.expneurol.2019.113063 (2019).
doi: 10.1016/j.expneurol.2019.113063
pubmed: 31518568
Piro, J. R. et al. Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. J. Neuroinflamm. 15, 142. https://doi.org/10.1186/s12974-018-1166-9 (2018).
doi: 10.1186/s12974-018-1166-9
Cooper, R. E. et al. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur. Neuropsychopharmacol. 27, 795–808. https://doi.org/10.1016/j.euroneuro.2017.05.005 (2017).
doi: 10.1016/j.euroneuro.2017.05.005
pubmed: 28576350
Lisboa, S. F. et al. Tempering aversive/traumatic memories with cannabinoids: A review of evidence from animal and human studies. Psychopharmacology 236, 201–226. https://doi.org/10.1007/s00213-018-5127-x (2019).
doi: 10.1007/s00213-018-5127-x
pubmed: 30604182
Hardt, S. et al. Loss of synaptic zinc transport in progranulin deficient mice may contribute to progranulin-associated psychopathology and chronic pain. Biochim. Biophys. Acta 2727–2745, 2017. https://doi.org/10.1016/j.bbadis.2017.07.014 (1863).
doi: 10.1016/j.bbadis.2017.07.014
Dalla Vecchia, E. et al. Cross-species models of attention-deficit/hyperactivity disorder and autism spectrum disorder: Lessons from CNTNAP2, ADGRL3, and PARK2. Psychiatr. Genet. 29, 1–17. https://doi.org/10.1097/ypg.0000000000000211 (2019).
doi: 10.1097/ypg.0000000000000211
pubmed: 30376466
Adeyemo, B. O. et al. Mild traumatic brain injury and ADHD: A systematic review of the literature and meta-analysis. J. Atten. Disord. 18, 576–584. https://doi.org/10.1177/1087054714543371 (2014).
doi: 10.1177/1087054714543371
pubmed: 25047040
Spencer, A. E. et al. Examining the association between posttraumatic stress disorder and attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. J. Clin. Psychiatry 77, 72–83. https://doi.org/10.4088/JCP.14r09479 (2016).
doi: 10.4088/JCP.14r09479
pubmed: 26114394
Rowe, R. K. et al. Diffuse traumatic brain injury induces prolonged immune dysregulation and potentiates hyperalgesia following a peripheral immune challenge. Mol. Pain https://doi.org/10.1177/1744806916647055 (2016).
doi: 10.1177/1744806916647055
pubmed: 27178244
pmcid: 4955995
van Hell, H. H. et al. Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology 219, 981–990. https://doi.org/10.1007/s00213-011-2428-8 (2012).
doi: 10.1007/s00213-011-2428-8
pubmed: 21822593
Wu, X. et al. Diagnosis and management of combined central diabetes insipidus and cerebral salt wasting syndrome after traumatic brain injury. World Neurosurg. 88, 483–487. https://doi.org/10.1016/j.wneu.2015.1010.1011 (2016).
doi: 10.1016/j.wneu.2015.1010.1011
pubmed: 26485413
Leonard, J. et al. Cerebral salt wasting after traumatic brain injury: A review of the literature. Scand. J. Trauma Resusc. Emerg. Med. 23, 98. https://doi.org/10.1186/s13049-015-0180-5 (2015).
doi: 10.1186/s13049-015-0180-5
pubmed: 26561391
pmcid: 4642664
Voikar, V. et al. Automated dissection of permanent effects of hippocampal or prefrontal lesions on performance at spatial, working memory and circadian timing tasks of C57BL/6 mice in IntelliCage. Behav. Brain Res. 352, 8–22. https://doi.org/10.1016/j.bbr.2017.08.048 (2018).
doi: 10.1016/j.bbr.2017.08.048
pubmed: 28927717
pmcid: 6102415
Radabaugh, H. L. et al. Refining environmental enrichment to advance rehabilitation based research after experimental traumatic brain injury. Exp. Neurol. 294, 12–18. https://doi.org/10.1016/j.expneurol.2017.04.013 (2017).
doi: 10.1016/j.expneurol.2017.04.013
pubmed: 28457905
pmcid: 5510462
Rabinak, C. A. et al. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiol. Learn. Mem. 113, 125–134. https://doi.org/10.1016/j.nlm.2013.09.009 (2014).
doi: 10.1016/j.nlm.2013.09.009
pubmed: 24055595
Danandeh, A. et al. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety. Psychopharmacology 235, 3211–3221. https://doi.org/10.1007/s00213-018-5020-7 (2018).
doi: 10.1007/s00213-018-5020-7
pubmed: 30251159
Gunduz-Cinar, O., Hill, M. N., McEwen, B. S. & Holmes, A. Amygdala FAAH and anandamide: Mediating protection and recovery from stress. Trends Pharmacol. Sci. 34, 637–644. https://doi.org/10.1016/j.tips.2013.08.008 (2013).
doi: 10.1016/j.tips.2013.08.008
pubmed: 24325918
pmcid: 4169112
Menzel, L. et al. Progranulin protects against exaggerated axonal injury and astrogliosis following traumatic brain injury. Glia 65, 278–292. https://doi.org/10.1002/glia.23091 (2017).
doi: 10.1002/glia.23091
pubmed: 27778404
Kramer, T. et al. Dimethyl fumarate treatment after traumatic brain injury prevents depletion of antioxidative brain glutathione and confers neuroprotection. J. Neurochem. 143, 523–533. https://doi.org/10.1111/jnc.14220 (2017).
doi: 10.1111/jnc.14220
pubmed: 28921587
Bishay, P. et al. Anandamide deficiency and heightened neuropathic pain in aged mice. Neuropharmacology 71, 204–215. https://doi.org/10.1016/j.neuropharm.2013.03.021 (2013).
doi: 10.1016/j.neuropharm.2013.03.021
pubmed: 23597506
Kanngiesser, M. et al. Hypoxia-inducible factor 1 regulates heat and cold pain sensitivity and persistence. Antioxid. Redox Signal. 20, 2555–2571. https://doi.org/10.1089/ars.2013.5494 (2014).
doi: 10.1089/ars.2013.5494
pubmed: 24144405
Altmann, C. et al. Progranulin overexpression in sensory neurons attenuates neuropathic pain in mice: Role of autophagy. Neurobiol. Dis. 96, 294–311. https://doi.org/10.1016/j.nbd.2016.09.010 (2016).
doi: 10.1016/j.nbd.2016.09.010
pubmed: 27629805
Altmann, C. et al. Progranulin promotes peripheral nerve regeneration and reinnervation: Role of notch signaling. Mol. Neurodegener. 11, 69. https://doi.org/10.1186/s13024-016-0132-1 (2016).
doi: 10.1186/s13024-016-0132-1
pubmed: 27770818
pmcid: 5075406
Krackow, S. et al. Consistent behavioral phenotype differences between inbred mouse strains in the IntelliCage. Genes Brain Behav. 9, 722–731. https://doi.org/10.1111/j.1601-183X.2010.00606.x (2010).
doi: 10.1111/j.1601-183X.2010.00606.x
pubmed: 20528956
Albuquerque, B., Haussler, A., Vannoni, E., Wolfer, D. P. & Tegeder, I. Learning and memory with neuropathic pain: Impact of old age and progranulin deficiency. Front. Behav. Neurosci. 7, 174. https://doi.org/10.3389/fnbeh.2013.00174 (2013).
doi: 10.3389/fnbeh.2013.00174
pubmed: 24319417
pmcid: 3837228
Fischer, C. et al. Prevention of age-associated neuronal hyperexcitability with improved learning and attention upon knockout or antagonism of LPAR2. Cell. Mol. Life Sci. https://doi.org/10.1007/s00018-020-03553-4 (2020).
doi: 10.1007/s00018-020-03553-4
pubmed: 32468095
Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676–682. https://doi.org/10.1038/nmeth.2019 (2012).
doi: 10.1038/nmeth.2019
pubmed: 22743772
Bishay, P. et al. R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One 5, e10628. https://doi.org/10.1371/journal.pone.0010628 (2010).
doi: 10.1371/journal.pone.0010628
pubmed: 20498712
pmcid: 2869361
Schmitz, K. et al. R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice. EMBO Mol. Med. 6, 1398–1422. https://doi.org/10.15252/emmm.201404168 (2014).
doi: 10.15252/emmm.201404168
pubmed: 25269445
pmcid: 4237468
Gurke, R. et al. Determination of endocannabinoids and endocannabinoid-like substances in human K3EDTA plasma—LC-MS/MS method validation and pre-analytical characteristics. Talanta 204, 386–394. https://doi.org/10.1016/j.talanta.2019.06.004 (2019).
doi: 10.1016/j.talanta.2019.06.004
pubmed: 31357310
Brunkhorst-Kanaan, N. et al. Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder. Metabolism 95, 65–76. https://doi.org/10.1016/j.metabol.2019.04.002 (2019).
doi: 10.1016/j.metabol.2019.04.002
pubmed: 30954559